FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2819457658> ?p ?o ?g. }

• W2819457658 endingPage "245" @default.
• W2819457658 startingPage "237" @default.
• W2819457658 abstract "<b><i>Background:</i></b> In a phase III study, sunitinib led to a significant increase in progression-free survival (PFS) versus placebo in patients with pancreatic neuroendocrine tumours (panNETs). This study was a post-marketing commitment to support the phase III data. <b><i>Methods:</i></b> In this ongoing, open-label, phase IV trial (NCT01525550), patients with progressive, advanced unresectable/metastatic, well-differentiated panNETs received continuous sunitinib 37.5 mg once daily. Eligibility criteria were similar to those of the phase III study. The primary endpoint was investigator-assessed PFS per Response Evaluation Criteria in Solid Tumours v1.0 (RECIST). Other endpoints included PFS per Choi criteria, overall survival (OS), objective response rate (ORR), and adverse events (AEs). <b><i>Results:</i></b> Sixty-one treatment-naive and 45 previously treated patients received sunitinib. By March 19, 2016, 82 (77%) patients had discontinued treatment, mainly due to disease progression. Median treatment duration was 11.7 months. Investigator-assessed median PFS per RECIST (95% confidence interval [CI]) was 13.2 months (10.9–16.7): 13.2 (7.4–16.8) and 13.0 (9.2–20.4) in treatment-naive and previously treated patients, respectively. ORR (95% CI) per RECIST was 24.5% (16.7–33.8) in the total population: 21.3% (11.9–33.7) in treatment-naive and 28.9% (16.4–44.3) in previously treated patients. Median OS, although not yet mature, was 37.8 months (95% CI, 33.0–not estimable). The most common treatment-related AEs were neutropenia (53.8%), diarrhoea (46.2%), and leukopenia (43.4%). <b><i>Conclusions:</i></b> This phase IV trial confirms sunitinib as an efficacious and safe treatment option in patients with advanced/metastatic, well-differentiated, unresectable panNETs, and supports the phase III study outcomes. AEs were consistent with the known safety profile of sunitinib." @default.
• W2819457658 created "2018-07-19" @default.
• W2819457658 creator A5000928175 @default.
• W2819457658 creator A5002648450 @default.
• W2819457658 creator A5004781307 @default.
• W2819457658 creator A5005262911 @default.
• W2819457658 creator A5013952219 @default.
• W2819457658 creator A5014078052 @default.
• W2819457658 creator A5015984085 @default.
• W2819457658 creator A5017947396 @default.
• W2819457658 creator A5020435379 @default.
• W2819457658 creator A5021032631 @default.
• W2819457658 creator A5021050968 @default.
• W2819457658 creator A5025634287 @default.
• W2819457658 creator A5029116476 @default.
• W2819457658 creator A5029343418 @default.
• W2819457658 creator A5031608841 @default.
• W2819457658 creator A5031890718 @default.
• W2819457658 creator A5032105752 @default.
• W2819457658 creator A5035064408 @default.
• W2819457658 creator A5036258878 @default.
• W2819457658 creator A5041251064 @default.
• W2819457658 creator A5043672686 @default.
• W2819457658 creator A5052609154 @default.
• W2819457658 creator A5059392900 @default.
• W2819457658 creator A5062381283 @default.
• W2819457658 creator A5067073528 @default.
• W2819457658 creator A5068300106 @default.
• W2819457658 creator A5071532685 @default.
• W2819457658 creator A5085102462 @default.
• W2819457658 creator A5085405229 @default.
• W2819457658 creator A5086944361 @default.
• W2819457658 date "2018-01-01" @default.
• W2819457658 modified "2023-10-14" @default.
• W2819457658 title "Efficacy and Safety of Sunitinib in Patients with Well-Differentiated Pancreatic Neuroendocrine Tumours" @default.
• W2819457658 cites W1977999028 @default.
• W2819457658 cites W2009619803 @default.
• W2819457658 cites W2032025076 @default.
• W2819457658 cites W2071901162 @default.
• W2819457658 cites W2098482546 @default.
• W2819457658 cites W2108045918 @default.
• W2819457658 cites W2113788015 @default.
• W2819457658 cites W2123684576 @default.
• W2819457658 cites W2128871558 @default.
• W2819457658 cites W2132550938 @default.
• W2819457658 cites W2144208206 @default.
• W2819457658 cites W2158474413 @default.
• W2819457658 cites W2166456106 @default.
• W2819457658 cites W2181053294 @default.
• W2819457658 cites W2189450260 @default.
• W2819457658 cites W2287643627 @default.
• W2819457658 cites W2549249508 @default.
• W2819457658 cites W2591156603 @default.
• W2819457658 doi "https://doi.org/10.1159/000491999" @default.
• W2819457658 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/29991024" @default.
• W2819457658 hasPublicationYear "2018" @default.
• W2819457658 type Work @default.
• W2819457658 sameAs 2819457658 @default.
• W2819457658 citedByCount "36" @default.
• W2819457658 countsByYear W28194576582018 @default.
• W2819457658 countsByYear W28194576582019 @default.
• W2819457658 countsByYear W28194576582020 @default.
• W2819457658 countsByYear W28194576582021 @default.
• W2819457658 countsByYear W28194576582022 @default.
• W2819457658 crossrefType "journal-article" @default.
• W2819457658 hasAuthorship W2819457658A5000928175 @default.
• W2819457658 hasAuthorship W2819457658A5002648450 @default.
• W2819457658 hasAuthorship W2819457658A5004781307 @default.
• W2819457658 hasAuthorship W2819457658A5005262911 @default.
• W2819457658 hasAuthorship W2819457658A5013952219 @default.
• W2819457658 hasAuthorship W2819457658A5014078052 @default.
• W2819457658 hasAuthorship W2819457658A5015984085 @default.
• W2819457658 hasAuthorship W2819457658A5017947396 @default.
• W2819457658 hasAuthorship W2819457658A5020435379 @default.
• W2819457658 hasAuthorship W2819457658A5021032631 @default.
• W2819457658 hasAuthorship W2819457658A5021050968 @default.
• W2819457658 hasAuthorship W2819457658A5025634287 @default.
• W2819457658 hasAuthorship W2819457658A5029116476 @default.
• W2819457658 hasAuthorship W2819457658A5029343418 @default.
• W2819457658 hasAuthorship W2819457658A5031608841 @default.
• W2819457658 hasAuthorship W2819457658A5031890718 @default.
• W2819457658 hasAuthorship W2819457658A5032105752 @default.
• W2819457658 hasAuthorship W2819457658A5035064408 @default.
• W2819457658 hasAuthorship W2819457658A5036258878 @default.
• W2819457658 hasAuthorship W2819457658A5041251064 @default.
• W2819457658 hasAuthorship W2819457658A5043672686 @default.
• W2819457658 hasAuthorship W2819457658A5052609154 @default.
• W2819457658 hasAuthorship W2819457658A5059392900 @default.
• W2819457658 hasAuthorship W2819457658A5062381283 @default.
• W2819457658 hasAuthorship W2819457658A5067073528 @default.
• W2819457658 hasAuthorship W2819457658A5068300106 @default.
• W2819457658 hasAuthorship W2819457658A5071532685 @default.
• W2819457658 hasAuthorship W2819457658A5085102462 @default.
• W2819457658 hasAuthorship W2819457658A5085405229 @default.
• W2819457658 hasAuthorship W2819457658A5086944361 @default.
• W2819457658 hasConcept C121608353 @default.
• W2819457658 hasConcept C126322002 @default.
• W2819457658 hasConcept C142724271 @default.

• next